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INTRODUCTION 
Radiotherapy, also called radiation therapy, is the 
treatment of cancer and other diseases with ionizing radiation. 
Ionizing radiation deposits energy that injures or destroys cells 
in the area being treated (the "target tissue") by damaging their 
genetic material, making it impossible for these cells to 
continue to grow. Although radiation damages both cancer cells 
and normal cells, the latter are able to repair themselves and 
function properly. Radiotherapy is indicated for majority of 
head and neck cancer patients. Depending on the extent and 
stage of the malignancy it can be either used alone or in 
combination with chemotherapy or surgery.  
Mucositis is the painful inflammation and ulceration of 
the mucous membranes lining the digestive tract, usually as an 
adverse effect of chemotherapy and radiotherapy treatment for 
cancer61 . Mucositis can occur anywhere along the 
gastrointestinal (GI) tract, but oral mucositis refers to the 
particular inflammation and ulceration that occurs in the mouth. 
Oral mucositis is a common and often debilitating complication 
of cancer treatment.66  
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Floyd had defined oral mucositis as the inflammatory 
change of the oral mucosa resulting from the direct effect of 
radiotherapy.  26  
According to Beumer et al,  inhibition of cell  growth and 
maturation by radiation disrupts the primary mucosal barrier of 
the mouth and throat and thereby creates a pathway for the 
establishment of oropharyngeal infection by resident oral 
microflora. The consequences of this include oral mucositis and 
gingivitis, oral candidiasis, xerostomia, trismus, dental caries, 
osteoradionecrosis, cellulitis, and viral mucosal eruptions.2 
 
Radiation Induced Damage To The Oral Mucosa 
 
The first clinical signs of radiation-induced mucositis 
occur at the end of the first week of a conventional seven-week 
radiation protocol (daily dose of 1.8 to 2.0 Gy, five times a 
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week). A white discoloration of the oral mucosa, which is an 
expression of hyperkeratinisation of the epithelium, followed 
by erythema, is initially seen. In other cases, a white 
discoloration maybe observed in combination with areas of 
erythema or erythema may appear first. The above clinical signs 
represent the grade I mucositis86 and are mostly asymptomatic. 
Towards the end of the second or around the third week of 
radiotherapy, small foci of ulceration can be observed, 
corresponding to the grade II mucositis. Patient complains of 
mild pain and can take soft diet. Severe, grade III mucositis 
presents as ulcers covered by pseudomembranes, affecting large 
areas of the oral mucosa . Grade IV mucositis represents even 
more severe ulceration, covering almost all mucosal surfaces. 
Patient complains of severe pain, can take liquids only or may 
necessitate nasogastric tube or parenteral support.  
Mucositis generally persists throughout radiotherapy, and 
develops at its maximum grade at the end of the irradiation 
period. One to three weeks or more, depending on the severity, 
are needed for mucositis to heal, after the completion of 
radiotherapy.  
Erythematous, ulcerated and xerostomic (dry) oral mucosa 
serves as site for the development of secondary infection. 
During a course of curative radiation, about 80% of the patients 
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will  develop different grades of mucositis.  Mucositis may be so 
severe as to delay treatment and so limit the effectiveness of 
cancer therapy.5 
The extent of the injury is directly related to the mucosal 
volume irradiated, anatomic subsite exposed, treatment 
intensity, and individual patient predisposition .  In radiotherapy 
mucositis is an integral part in terms of morbidity, as during a 
course of curative radiation the majority of patients will  
develop pseudomembranous mucositis.  OM from radiotherapy 
peaks at about weeks 5 to 6 and typically resolves during weeks 
8 to 12 of follow-up.25  
The early radiation reaction causes local discomfort as 
well as difficulties in drinking, eating, swallowing and speech. 
In head and neck radiotherapy these more aggressive regimens 
have been shown to improve local tumor control, but these are 
related to an increase in severe mucositis. This higher rates of 
acute toxicity result in higher levels of pain and difficulty in 
oral intake, and a significant worsening of the patient’s quality 
of life. Recent data have shown that more than half of the head 
and neck cancer patients (56%) who receive altered 
fractionation radiotherapy, will  experience more severe 
mucositis as compared to 34% of patients who receive 
conventional radiotherapy3.  
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Radiation damage is anatomically site-specific; toxicity is 
localized to irradiated tissue volumes. Degree of damage is 
dependent on treatment regimen-related factors including type 
of radiation used, total dose administered, and field 
size/fractionation. Head and neck radiation can also induce 
damage that results in permanent dysfunction of vasculature, 
connective tissue, salivary glands, muscle, and bone. Loss of 
bone vitality occurs secondary to both injury to osteocytes, 
osteoblasts, and osteoclasts as well as from a relative hypoxia 
due to reduction in vascular supply. These changes can lead to 
soft tissue necrosis and osteonecrosis that result in bone 
exposure, secondary infection, and severe pain.49  
Severe mucositis can give rise to nutritional problems, 
while hospitalisation and nasogastric feeding may become 
necessary. Rates of hospitalisation due to severe mucositis, 
reported in several studies, were 32% for altered fractionation 
radiotherapy and overall 16% of all  types of radiotherapy. 
Furthermore, about 10% and up to 30% of patients, depending 
mostly on the type of treatment, may necessitate an interruption 
or a modification and prolongation of the course of 
sradiotherapy because of severe mucositis 59 ,67. Interruptions 
and prolonged treatment adversely affect outcome and 
therapeutic effect. While oral complications primarily are 
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associated with discomfort and interference with oral function, 
in patients who are also immunocompromised or debilitated, 
these complications can become life threatening50. 
The Consensus Development Panel of the National 
Institutes of Health (Consensus statement, 1990) 52  stated that 
no drugs can prevent mucositis, an opinion that still holds to 
date. 
Consequently, treatment of mucositis is still limited to 
reduction of its severity. Oral care programs, relief of pain and 
discomfort, early diagnosis and treatment of concomitant 
secondary mucosal infections and/or strategies to eliminate 
micro-organisms, that are thought to promote or aggravate 
mucositis, are all engaged in its treatment. MASCC 48 and 
NCCN 16  guidelines and a National Cancer Institute report 
recommend “basic oral care” as a standard practice to  
prevent infections and potentially help alleviate mucosal 
symptoms.31,68 
The maintenance of oral hygiene during and after 
radiation will reduce the risk for dental complications, 
including infections, caries, gingivitis, and osteoradionecrosis. 
Basic oral care during radiation involves brushing in a 
nontraumatic fashion with a soft brush, flossing as tolerated, 
and frequent rinsing with bland solutions such as normal saline 
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with sodium bicarbonate (1 L water with 1/2 teaspoon baking 
soda and 1/2 teaspoon salt), the use of moisturizing agents, 
periodic dental evaluations and cleanings, and the use of 
lifelong daily dental fluoride prophylaxis 24 
Many different treatments are used to prevent or treat 
mucositis. General oral care protocols are to be followed. 
Mouthwashes with mixed action immunomodulatory agents, 
topical anesthetics, antiseptics, antibacterial, antifungal and 
antiviral drugs are used. Mucosal barriers, coating agents, 
cytoprotectants, mucosal cell stimulants, psychotherapy are 
also used in the management protocol. 
Many agents of differing mechanisms of action have been 
used in the prevention and treatment of oral mucositis induced 
by anticancer therapies. Currently, no intervention is 
completely successful at preventing or treating oral mucositis. 
The several solutions, drugs and methods used and studied in 
the prophylaxis and therapy of chemotherapy or radiotherapy-
induced oral mucositis reflects the need of new, more efficient 
tools in the management of this complication 14 
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AIMS AND OBJECTIVES 
 
1. To evaluate the effectiveness of pure natural honey on 
onset and severity of radiation - induced mucositis. 
 
2. To evaluate the effectiveness of benzydamine 
hydrochloride on onset and severity of radiation - 
induced mucositis. 
 
3. To compare the effectiveness of pure natural honey and 
benzydamine hydrochloride on onset and severity of 
radiation – induced mucositis with control. 
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REVIEW OF LITERATURE 
Head and neck irradiation can cause a wide spectrum of  
oral complications. Ulcerative oral mucositis is a virtually 
universal toxicity resulting from this treatment; there are 
clinically significant similarities as well as differences 
compared with oral mucositis caused by chemotherapy. 58,  69 ,  70 
Head and neck radiation can also induce damage that results in 
permanent dysfunction of vasculature, connective tissue, 
salivary glands, muscle, and bone. Loss of bone vitality occurs 
secondary to both injury to osteocytes, osteoblasts, and 
osteoclasts as well as from a relative hypoxia due to reduction 
in vascular supply. These changes can lead to soft tissue 
necrosis and osteonecrosis that result in bone exposure, 
secondary infection, and severe pain. 49 
Effect of radiation on oral and salivary gland tissues: 
Radiotherapy for head and neck tumours is a viable 
treatment modality. Radiotherapy is concerned with the 
delivery of the correct radiation dose to the tumour mass while 
minimizing the dose received outside the tumour zone. 
Rothwell states that most orofacial complications are dose 
dependent and that severe side effects occur when doses greater 
than 45 Gy are administered bilaterally to the mouth,jaws and 
salivary glands.  
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Teeth: 
Irradiation of teeth with therapeutic doses during their 
development severely retards their growth. Children receiving 
radiation therapy to the jaws may show defects in the 
permanent dentitions such as retained root development, 
dwarfed teeth or failure to form one or more teeth.13,27 ,71 
Radiation caries is a rampant form of dental decay that 
may occur in individuals who receive a course of radiotherapy 
that includes exposure to salivary glands. The carious lesions 
result from changes in the salivary glands and saliva, including 
reduced flow, decreased pH, reduced buffering capacity and 
increased viscosity.Irradiation of teeth by itself does not 
influence the course of radiation caries87. 
Bone: 
The primary damage to mature bone results from radiation 
induced damage to the vasculature of the periosteum and 
cortical bone. Radiation also acts destroying osteoblasts and to 
a lesser extent, osteoclasts..Subsequent to radiation, normal 
marrow may be replaced with fatty marrow and  fibrous 
connective tissue. The marrow tissue becomes hypovascular, 
hypoxic and hypocellular. When these changes are so severe, 
that sbone death results, the condition is termed 
Osteoradionecrosis 23 ,47 ,54 
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Effect of radiation on salivary glands: 
Ionising radiation causes glandular tissue damage, which 
may result in a rapid, irreversible loss of salivary fluid 
secretion. The glandular architecture is replaced by ductal 
remnants and loose fibrous connective tissue which is 
moderately infiltrated with lymphocytes and plasma cells. This 
progressive glandular, atrophy, fibrosis and reduced salivary 
output begins slowly after initial exposure and intensifies there 
after 50 . 
Taste buds: 
Taste buds are sensitive to radiation. Patients often note 
loss of taste acuity during the 2nd and 3rd week of radiotherapy, 
which may proceed to a state of virtual in sensitivity, with 
recovery to near normal level, some 60 to 120 days after 
irradiation54 ,87 
The severity of oral mucositis can range from barely 
perceptible mucosal erythema and atrophy to severe mucosal 
inflammation and ulceration. Oral mucositis can obviously 
cause severe pain and add significantly to the morbidity of 
cancer therapy. Oral tissue damage and pain can result from a 
number of different processes related not only to the cancer 
therapy but also to a number of patient-related factors as well 72 
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Mucosal Characteristics 
The primary function of oral mucosa is to serve as a 
barrier that protects the underlying tissues and organs 73 .  The 
tissues of the oral cavity are continually subjected to a wide 
variety of traumatic insults associated with oral function and 
are under constant pressure from a wide variety of microflora 
inhabiting the oral cavity. Key to withstanding these insults is 
the ability of the basal cells in the deeper germinative layers of 
the oral epithelium to continually divide and follow an orderly 
process of maturation and migration, culminating in 
desquamation at the surface. Comparatively, the turnover rate 
(time from basal replication to desquamation) for the oral 
mucosa is less than that of the gut epithelium but greater than 
that of skin. The epithelial renewal rate for oral mucosa varies 
with different anatomical areas of the mouth with the 
nonkeratinized lining mucosa (e.g., ventral tongue, labial 
mucosa, soft palate) having rates that have been estimated to be 
1.5 to five times greater than masticatory mucosa (e.g., 
attached gingiva, hard palate) 62 . The epithelial cells of the oral 
mucosa undergo rapid turnover, usually every 7 to 14 
days,which makes these cells sustain effects of cytotoxic 
therapy50 . Radiation therapy and chemotherapy primarily 
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damage and kill dividing cells by damaging DNA or interfering 
with cell division.  
 Saliva serves a broad spectrum of physiologic needs 
relative to oral health and function45 ,46. The functions of saliva 
include (a) lubrication of oral tissues (and food) to prevent 
physical trauma and irritation, (b) hydration of mucosal 
surfaces, and (c) modulation and control of microbial 
colonization and growth due to the presence of salivary 
proteins, antibodies, and other proteins with antimicrobial 
actions.. Consequently, salivary gland dysfunction will not only 
result in complaints of a ``dry mouth' ' but will also increase the 
risk of trauma and irritation to oral tissues and increase the risk 
of oral mucosal infections74 
In addition to the damage to the mucosal epithelium, 
radiation causes damage and subsequent changes in the 
submucosal connective tissue and vasculature, even though the 
cellular proliferation rate and turnover in these tissues is much 
lower44.  Damage to the connective tissue component of the oral 
mucosa is noted as hyalinization of collagen, depolymerization 
of large molecules making up the ground substance, increased 
vascular permeability, tissue edema, and presence of an 
inflammatory infiltrate 6 ,66. Radiation to the endothelial cells of 
the small vessels and capillaries results in vasculature damage 
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that reduces functional efficiency of the vessels. Osseous 
damage from radiation results in: marrow avascularity and fatty 
degeneration; reduction of osteocytes, osteoblasts, and 
osteoclasts; and microfractures and enlarged lacunae 78 . Many 
of the chronic complications of radiation therapy result from 
nonrepairable damage to the vasculature, connective tissue, and 
bone cells that leads to hypovascularity, tissue ischemia, 
fibrosis, and nonvital bone44.   
 
Biological stages of mucositis 
 
The five biological stages of mucositis can be defined as 
initiation, primary damage response, signal amplification, 
ulceration and healing. 
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Initiation 
The initiation stage of tissue injury occurs rapidly 
following the administration of radiation or chemotherapy. 
Radiation and chemotherapy initiate both DNA and non-DNA 
damage. DNA strand breaks result in direct cellular injury that 
targets cells in the basal epithelium as well as cells within the 
submucosa. Simultaneously, reactive oxygen species (ROS), 
which are crucial mediators of downstream biological events, 
are generated. Although the mucosa seems to be absolutely 
normal at this stage, a cascade of events begins in the 
submucosa that ultimately results in mucosal destruction. 
Denham and Hauer-Jensen reported that although there is death 
of some cells within the basal and suprabasal epithelium, it  is 
the destruction of the cells in the underlying submucosa that 
makes the largest contribution to injury17. 
Primary Damage Response 
DNA damage, non-DNA damage and ROS initiate an 
interesting and complex series of events that is still being 
defined. DNA strand breaks result in the activation of several 
transduction pathways that activate transcription factors such as 
p53 and nuclear factor-κB (NF-κB)11  NF-κB is activated in 
response to radiation, several chemotherapeutic drugs and ROS( 
Cell-membrane-bound molecules that are released during lipid 
16 
 
peroxidation result in the upregulation of immediate-response 
genes, such as those encoding c-JUN and and c-JUN amino-
terminal kinase (JNK)18  These upregulate other transcription 
factors, such as NRF2 (REF. 36). Importantly, all of these 
changes occur in all of the cells and tissues that comprise the 
mucosa — not just in the epithelium. 
Among the transcription factors that are activated by 
radiation, chemotherapy and ROS, NF-κB has been suggested to 
be one of the most significant, in relation to both toxicity and 
resistance of tumours to therapy. 39 ,10  
Signal Amplification 
As a consequence of the gene upregulation that is brought 
about by the initial activation of transcription factors, a broad 
range of biologically active proteins accumulate and target the 
tissues of the submucosa. Some of these, particularly the pro-
inflammatory cytokines, not only damage tissue, but also 
provide a positive-feedback loop to amplify the primary damage 
that is initiated by radiation or chemotherapy. This pathway 
ultimately results in the activation of caspase 3 and in cell 
death18.  Importantly, although the mucosal cellular targets 
include the epithelium, they also include elements of the 
submucosa. TNF-α also activates sphingomyelinase. So, its 
increased level in the tissue amplifies pro-apoptotic signals that 
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are mediated by the ceramide pathway. In addition, both TNF-α  
and IL-1β  induce MMP1 and MMP3 activation.7 ,82.  It  is 
noteworthy that while the ravages of biological chaos are 
occurring during the initial phases of mucositis, the clinical 
picture is one of quiescence. Although there might be some 
mucosal erythema during these stages, for the most part, tissue 
integrity is in place and patients have few symptoms. This 
changes as ulceration develops. 
Ulceration 
The ulcerative phase of mucositis is the most significant 
to both the patient and the caregiver. The loss of mucosal 
integrity results in extremely painful lesions that are prone to 
superficial bacterial colonization. In the case of neutropenic 
patients, these breaks in the mucosa serve as portals of entry 
for the numerous microorganisms that reside in the mouth, and 
often lead to bacteraemia and sepsis. In addition, cell-wall 
products from colonizing bacteria are likely to penetrate into 
the submucosa, where they activate infiltrating mononuclear 
cells to produce and release additional pro-inflammatory 
cytokines19.  This probably promotes the expression of pro-
apoptotic genes1  and potentiates tissue injury. Inflammatory 
cells then migrate by chemotaxis to the base of the lesion, 
where they produce damaging enzymes. 
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Healing 
In most cases, mucositis is an acute phenomenon that is 
self-resolving once cancer therapy ends. Although there are 
parallels between the resolution of mucositis-induced ulcers 
and the healing of other types of mucosal injury, it is likely that 
the sequence of events that leads up to mucositis modulates the 
process. Signals from the submucosal extracellular matrix and 
mesenchyme govern the rate of epithelial-cell migration, the 
rate of proliferation and the differentiation of healing tissue. 
The course of tissue behaviour must be regulated to some 
degree by the type of cancer treatment (radiation versus 
chemotherapy), the agents selected and the dose and timing of 
therapy. 
In addition to mucosal damage, ionizing radiation can 
cause significant salivary gland dysfunction, although the exact 
mechanism of the damage is not clear 32 ,45,46 ,73.  Damage does 
not appear to be entirely due to direct acinar damage and there 
is some evidence suggesting that damage to ductal epithelium 
and vasculature may be responsible for the decreased salivary 
flow rates. Damage to the major and minor salivary glands by 
radiation also reduces levels of salivary antibodies and other 
antimicrobial proteins and glycoproteins, which contributes to 
increased mucosal irritation and infection. Additionally, saliva 
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 becomes more acidic and more mucinous in character 
45 ,46 ,62 ,73.   
Different agents have been used for the prophylaxis as 
well as management of Radiation-induced mucositis. Pain 
management is the single most important aspect of symptom 
control during HN radiation  20 The agents recommended or 
tested for the prevention and management of radiation induced 
mucositis, have targeted specific pathways and they include 
mucosal coating agents, anti-inflammatory agents, 
antimicrobials, immunomodulators, anesthetics and analgesics, 
and other agents that are difficult to classify. 
These locally applied as well as systemically taken agents 
have been supportive at most, consisting of measures to 
alleviate pain and improve discomfort, support adequate 
hydration and, in some, the ability to eliminate 
secondary infections 88. 
B. M. Biswal et al 2001  studied the effect of topical 
application of pure natural honey on radiation- induced oral 
mucositis. There was significant reduction in the symptomatic 
grade 3 and 4 mucositis among honey-treated patients compared 
to controls; i.e. 20% versus 75% (p 0.00058).The compliance of 
honey-treated group of patients was better than controls. The 
difference in grade3 and 4 mucositis was 20% and 75% 
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respectively in the treatment and control arm (p< 0.00058).Thus 
in this study it  was seen that although there was no significant 
change in grade 1 & 2 mucositis, grade3 & 4 mucositis was 
significantly reduced in the treatment arm.4 
Motallebnejad et al in 2004  studied the effect of topical 
application of pure natural honey on radiation mucositis. In this 
randomized  single blind clinical trial with 40 patients, it was 
observed that the mucositis score of OMAS( Oral Mucositis 
Assessment Scale)76  at the end of each week in the study group 
was significantly lower than the control group (p=0.000) thus 
showed that honey had a remarkable effect on radiation 
mucositis.  43 
Rashad U M et al in 2006  studied the efficacy of pure 
natural honey as prophylaxis against radiochemotherapy-
induced mucositis. In this clinical trial of 40 patients, it  was 
observed that only 15% of patients (3 patients) developed grade 
3 mucositis, none in treatment group developed grade 4 
mucositis. In the control group, 13 patients developed grade 3 
or 4 mucositis (p< 0.05). 
This study shows that prophylactic use of pure natural 
honey was effective in reducing mucositis resulting from 
radiochemotherapy in patients with head and neck cancer  63. 
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    Khanal et al in 2010  in a single-blinded, randomized, 
controlled clinical trial, comparing natural honey and 
lignocaine, observed that only one in honey group developed 
intolerable oral mucositis compared with lignocaine group, 
indicating that honey is strongly protective against the 
development of mucositis. The proportion of patients with 
intolerable oral mucositis was lower in the honey group and 
this was statistically significant (p= 0.000).32 
Joel B Epstein et al in 2001  evaluated the effect of 
0.15% benzydamine hydrochloride on Radiation- induced 
mucositis. In this study it  was observed that during 
conventional RT,regimens upto cumulative does of 5000 cGy, 
benzydamine (n= 69) significantly (p= 0.006) reduced erythema 
and ulceration by approximately 30% compared with the 
placebo (n= 76); greater than 335 of benzydamine subjects 
remained ulcer free compared with 18% of placebo subjects            
(p= 0.037%), and benzydamine significantly delayed the use of 
systemic analgesics compared with placebo (p< 0.05). 
Benzydamine was not effective in subjects (n= 20) receiving 
accelerated RT doses (>- 220cGy/day).  22 
In a double-blind/ placebo study was undertaken in order 
to ascertain the possible oral histoprotective effect of 
benzydamine mouthwash during the intra-arterial 
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polychemotherapy and/or radiotherapy for neoplasms of the 
head and neck. Statistical comparison of the results obtained in 
these two groups, treated with benzydamine and placebo 
mouthwash, revealed a marked difference in the clinical 
evolution of iatrogenic tissue damage. The benzydamine topical 
application was more effective than placebo in the control of 
mucositis symptoms and signs produced by radiotherapy and / 
or intra arterial antineoplastic chemotherapy.29 
Kazemian A et al in 2005 studied the effect of 
benzydamine oral rinse on radiation mucositis and the results 
showed that the frequency of mucositis grade> or = 3, was 
43.6% in contrast to 78.6% in other group (p= 0.001).Grade > 
or = 3 mucositis was 2.6 times more frequent in the placebo 
group. Intensity of mucositis increased upto 4th week of 
treatment in both groups to grade 2.In the treated group the 
grade of mucositis was approximately constant to the end of 
therapy; but in the control group it raised to grade 3(p< 0.01).In 
this study it was inferred that benzydamine oral rinse seems to 
be effective, safe and well tolerated for prophylactic treatment 
of RIM in H& N cancers 33.  
Kim JH et al  (American journal of Clinical Oncology. 
1986 apr;9(2):132-4.) in a double-blind, randomized clinical 
investigation studied the effect of benzydamine in radiation 
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induced mucositis. patients developed radiation 
mucositis,hyperemia,and throat pain when the total radiation 
dose reached above 2,000 rad over 2 weeks .Analysis of the 
data showed that benzydamine Hcl used as a rinse/gargle 
provided a statistically significant and clinically meaningful 
alleviation of the symptoms of oropharyngeal mucositis .34 
Kamian et al in 2007 studied the effect of benzydamine 
hydrochloride on radiation mucositis in a randomized placebo 
controlled clinical trial. In this study it was observed that 
frequency of mucositis of grade 3 or more was found in placebo 
group compared to benzydamine group. The difference was 
statistically significant (p=0.001) oral rinse benzydamine was 
effective, safe, and well tolerated for prophylactic treatment of 
radiation-induced oral mucositis in head and neck tumors.  35  
King- fong cheng et al in 2006  in a prospective, 
randomized, and double blinded Studys, compared the efficacy 
of 0.2% chlorhexidine gluconate and 0.15% benzydamine 
hydrochloride oral rinses in alleviating irradiation mucositis for 
patients with head and neck cancer. The subjects were 
evaluated based on World Health Organization mucositis scale 
and the 10-cm visual analogue scale for mouth pain and 
dysphagia from this study, it was inferred that there was 
lessening of severity of mucositis, pain, and dysphagia for 
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patients with head and neck cancer receiving benzydamine oral 
rinse36. 
Samaranayake et al 1986 studied the the effect of 
benzydamine and chlorhexidine mouthwashes on radiation 
induced mucositis. Its efficacy as a mouthwash was compared 
with chlorhexidine in two groups of patients receiving 
radiotherapy for oral carcinoma. In this study it was noted that 
there was little difference between the two mouthwashes both 
in controlling pain and mucositis or in the oral carriage of the 
micro-organisms studied. 77  
Symonds R P et al in 1996  evaluated the effect of 
antibiotic pastilles on radiation mucositis, pain, dysphagia and 
weight loss in patients undergoing radical radiotherapy for head 
and neck cancer, in which it was observed that there was a 
considerable reduction in mucositis distribution, dysphagia, 
weight loss in the patients using antibiotic pastilles, indicating 
that the active pastilles had a beneficial effect on radiation 
induced oral mucositis.78 
N. Kantardzic, V. Smajlbegovic, N. Kazic & A. Cardzic  
in 2008  evaluated the  effectiveness of gelclair oral gel in the 
treatment of oral mucositis in patients with head and neck 
tumours during radiotherapy or/and chemotherapy. It  was 
inferred from this study that there was a significant 
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improvement in management of pain and significant 
improvement in food intake in the study group.55  
Cristina bez et al in 2008  evaluated the effect of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) 
mouthrinses as a potential treatment in reducing the duration of 
severe oral mucositis in patients undergoing bone marrow 
transplantation for hematologic malignancies. It was seen in 
this study that 60% of the GM-CSF mouthrinse patients had 
severe mucositis for less than 9 days, whereas only 28% of the 
controls had severe mucositis for less than 9 days. In addition, 
10% of the GM-CSF mouthrinse patients experienced severe 
mucositis lasting 20 or more days, whereas 34% of the controls 
experienced severe mucositis for 20 or more days. It  was 
inferred in this study that GM-CSF used as a rinse reduced the 
duration as well as severity of radition – induced mucositis.12 
McAleese J J et al in 2000 assessed the effect of 
subcutaneous GM-CSF injections on acute radiation morbidity 
in patients undergoing accelerated radiotherapy for laryngeal 
cancer.In this prospective, randomized, observer-blind phase II 
trial, it was seen that mean duration of severe mucositis was 
less in GM-CSF group compared to the control group 51. 
Kannan et al in 1997  in a pilot study evaluated the effect 
of GM-CSF mouth rinse on radiation induced mucositis. The 
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results showed that GM-CSF mouthrinse administration 
concurrently with conventional fractionated radiotherapy was 
feasible without significant toxicity. The acute side effects of 
radiotherapy namely mucositis, pain, and functional impairment 
were nil to minimal. The results are suggestive of mucosal 
protection by GM-CSF during radiotherapy.37  
Meredith et al in 1997 in a double blind study, studied 
whether the addition of the ulcer-coating polysaccharide, 
sucralfate could improve symptomatic relief of radiation 
mucositis over a popular combination of antacid, 
diphenhydramine, and viscous lidocaine alone. There was 
statistically significant reduction in symptomatic radiation 
mucositis in the sucralfate group 65. 
            Etiz D et al in 2000 evaluated the effect of sucralfate 
on prevention of radition induced mucositis. In this 
prospective, randomized, clinical trial, it  was inferred that 
sucralfate may be used as an preventive agent in the 
management of radiation induced mucositis.  21 
PD Madan Kumar, PS Sequeira, Kamalaksha Shenoy, 
Jayaram Shetty 2005 in a randomized clinical trial evaluated 
the effect of of three mouthwashes (0.12% chlorhexidine, 1% 
povidone-iodine, or salt/soda) on radiation-induced oral 
mucositis in patients with head and neck malignancies. The 
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results showed that patients in the povidone-iodine group had 
significantly lower mucositis scores when compared to the 
control group from the first week of radiotherapy. Oral 
mucositis due to antineoplastic radiotherapy.42 
David M Brizel et al in 2000 in a randomized clinical 
trial, evaluated the effect of Amifostine as a radioprotector in 
patients undergoing radiotherapy. Amifostine was administered 
before irradiation. Amifostine reduced grade ≥  2 acute 
xerostomia from 78% to 51% (P  < .0001) and chronic 
xerostomia grade ≥  2 from 57% to 34% (P  = .002). Median 
saliva production was greater with amifostine (0.26 g v  0.10 g, 
P  = .04). Amifostine did not reduce mucositis15 
Dosia Antonadou et al in 2002 studied the prophylactic 
properties of amifostine against acute and late toxicities from 
radiochemotherapy in patients with head-and-neck cancer.  In 
this randomized clinical trial, it was observed that amifostine 
reduced the grade IV mucositis and xerostomia.16  
Kouvaris J et al studied the cytoprotective impact of 
amifostine against acute radiation mucositis. A significantly 
reduced severity of symptomatology related to oral, esophageal 
mucosa was noted in the amifostine group (p < 0.05).38 
Ricardo Spielberger et al in 2004  in a double blind 
study, evaluated the effect of Palifermin with that of placebo on 
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mucositis in patients with hematologic malignancies. The mean 
duration of mucositis was 6 days in palifermin group. 
Compared to 9 days in control group 63% of palifermin group 
had severe mucositis(Grade 3 or 4 (WHO Mucositis Grading) 
compared to 98% in placebo group.64 
Johannes et al in 1994  studied the effect of topical 
application of antibiotic pastilles in radiation induced mucositis 
Lozenges containing polymyxin E, tobramycin, and 
amphotericin B (PTA-lozenges) were polymyxin E, tobramycin, 
and amphotericin B may reduce irradiation mucositis of the oral 
cavity.28  
Fred K. L. Spijkervet et al studied the effect of lozenges 
containing Polymyxin E, tobramycin, amphotericin B on 
radiation induced mucositis In this study it was observed that 
mucositis was significantly reduced in the study group20.  
Somkit Penpattanagul in 2007 evaluated the role                   
of WF10-immunotherapy in reducing oro-pharyngeal 
complications in head and neck cancer chemoradiotherapy. 
Patients in the study that WF10 reduces the incidence of oro-
pharyngeal complications, (including oral mucositis, dysphagia, 
oral pain), taste alteration and weight loss. The statistical 
significances were achieved for the parameters of oral 
mucositis (p = 0.048) and dysphagia (p = 0.009). 80 
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MATERIALS AND METHODS 
This study was conducted in The Department of Oral 
Medicine and Radiology, Tamilnadu Govt. Dental College & 
Hospital, Chennai-600003, and The Department of Radiation 
Oncology, Government General Hospital,Chennai-600003 from 
april 2010 to December 2010 after getting  approved by the 
Institutional Ethical committee. The sample size comprised of 
60 patients, of both genders within age groups of 30 years to 70 
years, diagnosed with oral malignancy clinically and 
histopathologically.  Of the sixty patients, the group comprised 
of 42 males and 18   females within ages of 30 to 70. The 
minimum age of female was 30 years of age and the maximum 
age was 65 years. The minimum age of male was 34 and the 
maximum age was 70 years (Table 7). 
The patients were assigned into three groups by random 
sampling. Each group consisted of 20 patients. Group1 
comprised of 11 (55%) males and 9 (45%) females. Group 2 
comprised of 15 (75%) males and 5 (25%) females. Group 
3(Control) comprised of 15 (75%) males and 5 (25%) females. 
In the group 1,the location of malignancies(Ca) were: Floor of 
mouth-1 patient,  buccal mucosa -6 patients,Tongue-4 patients, 
Upper alveolus-3 patients, Lower alveolus-2patients,softpalate-
3 patients, maxillary antrum-1patient(Table 4).The TNM 
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staging was done for group 1.The number of patients with TNM 
staging were: Stage I:No patient, Stage II:1 patient, Stage III: 1 
patient, Stage IVa:16 patients, Stage IVb: 2 patients(Table 5). 
In the group 2, the location of malignancies (Ca) were: 
Floor of mouth-no  patient,  buccal mucosa-5patients,Tongue-
3patients Upper alveolus-5 patients, lower alveolus-4 
patients,softpalate-2 patients, maxillary antrum-1 patient  
(Table 4).  The TNM staging was done for group 2.The number 
of patients with TNM staging were: Stage I:No patient, Stage 
II:1 patient, Stage III: No patient, Stage IVa:16 patients, Stage 
IVb: 2 patients(Table 5). 
In the group 3(Control),the location of malignancies(Ca) 
were: Floor of mouth-2 patients, Ca buccal mucosa-7 
patients,Tongue-3 patients Upper alveolus-3 patients, lower 
alveolus-2 patients, soft palate-3 patients ,maxillary antrum-no 
patients (Table 4) .  The TNM staging was done for group 3.The 
number of patients with TNM staging were: Stage I:No patient, 
Stage II:2 patients, Stage III: No patient, Stage IVa:17 patients, 
Stage IVb: 1 patient(Table 5). 
In The Department of Oral Medicine and Radiology, 
Tamilnadu Govt. Dental College & Hospital, Chennai-600003, 
the sample subjects underwent complete extra-oral and intra-
oral examinations. 
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Armamentarium required for clinical examination (Fig 1): 
Mouth mirror 
Probe   
Tweezer 
Mask and glove 
Good illumination. 
Clinical examination of the oral cavity and the 
surrounding structures were done and the clinical findings 
recorded in a structured proforma designed for the study. Intra 
oral (IOPAs and Occlusal views of Maxilla and Mandible) and 
extra oral radiographs (PNS view, OPG, Lateral and 
Anteropostreior skull views etc) were taken at the sites of the 
lesion to find out any erosion of alveolar bone ,extent of the 
lesion and  any other associated lesions. Preliminary laboratory 
investigations including complete blood investigations like 
Total count, differential counts of WBC’s, RBC count, 
hemoglobin level, bleeding and clotting times, the peripheral 
smear etc were done. Patients were referred to the ICTC for test 
for HIV .All the findings were recorded in the structured 
proforma designed for the study. The staging of the malignancy 
was done based on the TNM staging system. 
The patients were given habit counselling regarding 
stopping of the habit of Tobacco usage both in smoking and 
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chewing form. The patients were motivated for cessation of the 
habit. 
The patients were advised on basic oral hygiene Oral 
prophylaxis was done. Conservative management with 
restorations were done for amenable teeth. Extractions of 
necessary teeth with poor prognosis with poor periodontal 
condition and in the field of radiation were done.  The patients 
were then referred to the Dept of Radiation Oncology, 
Government General Hospital, Chennai-600003, for 
Radiotherapy. 
Inclusion criteria: 
1. 60 individuals who were planned to undergo a minimum of 
6weeks of radiation treatment for oral malignancy were 
selected.  
2. Males and nonpregnant female subjects 30-70 years old 
who were clinically and histopathologically diagnosed 
with oral malignancies, who were scheduled to receive a 
total external beam RT dose of atleast 6000cGy via a 
megavoltage treatment with a cobalt -60 teletherapy unit 
were eligible for the study. 
Exclusion criteria: 
1. Patients not willing to participate in the study 
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2. Patients having systemic illnesses (for eg: Diabetes, 
Hypertension etc) 
3. Patients with prior history of radiotherapy for any 
malignancies and patients with concurrent chemotherapy. 
4. Patients having residual oral or pharyngeal mucositis from 
previous radiotherapy or chemotherapy. 
5. Patients taking analgesics for other medical conditions 
6. Patients with history of allergy to honey or benzydamine 
hydrochloride  
7. Pregnant patients. 
PROCEDURE  
All the patients,included in the study were explained 
about the study.Informed consent for the study to be carried out 
on the patients were obtained both verbally and in written ,both 
in local language and in english Cobalt- 60 equipment (Fig 2) 
was  used for radiation treatment.The equipment consists of  a 
cylinder of diameter 2 cm., height 5 cm., and is positioned in 
the Cobalt Unit with the circular end facing the patient. Cobalt-
60 Gamma radiation typically has energy of about 1.2 MV, D-
max being 0.5 cm. and a percentage depth of 55% at 10 cm. 
Cobalt units with low energy of gamma rays are used for 
treatment of head and neck cancers.  
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Conventional fractionated radiation was delivered to the 
tumour volume at a dose rate of 2  Gy per fraction,treating five 
fractions per week to a total period of 6-7 weeks. The weekly 
dosage was 10 Gy( Gray).The total dosage given varied from 60 
to 70 Gy( 6000 to 7000 cGy). 
Radiation source, modality,field size,treatment areas,total 
planned dose,number of fractions,days of irradiation were 
recorded in the structured proforma prepared for the study.  
Assessment of tumour response and complication development 
were monitored weekly at the radiotherapy review clinic. 
Baseline liver function tests, Kidney function tests and Blood 
sugar levels were assessed  before the start of the study and the 
end of the study. 
Armamentarium(Study materials) used in our study are (Fig 4) 
1. Pure natural honey – Brand name: Dabur honey 
2. 0.15%w/v Benzydamine hydrochloride – Brand name: 
Tantum oral rinse. 
3. 0.9% Normal saline. 
Patients were divided into three groups by simple random 
sampling.  
Each group comprised of 20 patients. 
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GROUP I: 
    In the group I, the patients were instructed to take 20 ml of  
pure natural honey (Fig 5(a)  )15 minutes before radiotherapy. 
They were instructed to slowly rinse the honey in their mouths, 
swish it  around for 5 minutes duration, so as to make the honey 
in contact of the oral mucosa and slowly swallow so as to make 
contact with the pharyngeal mucosa (Fig 5(b) ). The patients 
were exposed to therapeutic radiation. After 15 mins of this, 
again 20 ml of pure natural honey is given to the patient to be 
followed as before.After 6 hours of the radiotherapy, the 
patients were instructed to again rinse and swallow with 20 ml 
of pure natural honey and advised to be followed as before. 
GROUP  II : 
Patients were instructed to rinse with 15ml of  0.15% 
benzydamine Hcl without dilution (fig 6(a)  ),for 5 mins 
duration,15 minutes before and 15 mins after RT. The patient 
should be instructed to keep the rinse in contact with the oral 
mucosa for atleast 5 minutes duration, and then spit it out             
(Fig 6(b) ). The patients were exposed to therapeutic radiation. 
After 15 mins of this, the patients were asked again  to rinse 
with 15 ml of 0.15%w/v benzydamine hydrochloride , for 5 
minutes duration and then spit it  out. After 6 hours of the 
radiotherapy, the patients were instructed to again rinse with 15 
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ml of 0.15% w/v benzydamine hydrochloride for a duration of 5 
minutes and then spit it out. 
GROUP III(Control group) : 
 Patients were instructed to rinse with 20ml of  0.9%w/v 
Normal saline (Fig 7(a) )for 5 mins duration. The patient 
should be instructed to keep the rinse in contact with the oral 
mucosa for atleast 5 minutes duration, and then spit it out           
(Fig 7(b) .   
The patients were exposed to therapeutic radiation. After 
15 mins of this, the patients were asked again to rinse with 20 
ml of 0.9% Normal saline, for 5 minutes duration and then spit 
it out. After 6 hours of the radiotherapy, the patients were 
instructed to again rinse with 20ml 0.9%w/v of normal saline 
for a duration of 5 minutes and then spit it out. 
GRADING OF MUCOSITIS: 
All the patients were clinically examined from day 1 of 
RT, throughout the RT regimen and two weeks after completion 
of RT for development of oral mucositis. 
The complete oral examinations were done everyday for 
the patients in the three groups. The clinical grading of 
mucositis was done according to WHO Mucositis Grading. 
The onset of mucositis, clinically seen as erythema and 
soreness without ulceration and without any problems of 
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alimentation, was noted for every patient as Grade I.The day of 
onset of grades II, III,and IV were noted during the course of 
radiotherapy. 
          After the radiotherapy treatment schedule, the patients 
were clinically examined for the gradings of mucositis at the 
end of 1st  week after radiotherapy and end of 2nd week after 
radiotherapy.The findings were recorded in the structured 
proforma. 
STANDARDISATION: 
1. Pure natural honey- Brandname: Dabur Honey. 
The pure natural honey used in our study was Dabur 
Honey. Honey is the by-product of flower nectar and the upper 
aero-digestive tract of the honeybee,which become concentrated 
by the dehydration process inside the bee-hive. They contain 
moisture, fructose, glucose, sucrose, maltose and other 
compounds, along with trace elements. Pure natural honey                
is ubiquitous, cheap, and natural, and exhibits antibacterial, 
analgesic and tissue nutritive factors to stimulate re-
epithelialisation in the damaged mucosa. Honey has been found 
effective in burn wounds, oral infections and acceleration of 
surgical wound healing. 
Honey has anti-bacterial properties and enhances 
epithelialization, thereby improving wound healing. We have 
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used natural honey (Dabur honey)for the treatment of radiation 
mucositis to enhance epithelialization of the mucosa, thereby 
reduce morbidity. 
Standardisation of honey: 
a. The pure natural honey used for the study was Dabur 
Honey. 
b. The Dabur honey conforms strictly with all statutory 
requirements of Agmark,the PFA and the International 
norms for purity. 
c. Dabur honey scored the highest on the main parameters of 
honey purity in recent analysis of all the Indian brands 
and also obtained ASHCO certification for quality and 
HACCP (Hazard Analysis and Critical Control Points) 
certification. 
QUALITY CONTROL OF DABUR HONEY: 
1.  Dabur honey sourced selectively from the Himalayas, the 
Nilgiris and the Sunderbans forests  
2 .  2.Collection process follows stringent quality checks to 
ensure even raw unfiltered honey is of best quality 
3.  .Entire process is mechanized and untouched by hands to 
ensure hygienic conditions  
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2.0.15%w/v Benzydamine hydrochloride- Brand name : 
Tantum oral rinse 
The 0.15% w/v benzydamine hydrochloride used in the 
study was Tantum soral rinse. Tantum is benzydamine oral 
rinse containing 0.15% Benzydamine Hcl a non-steroidal anti- 
inflammatory agent in a flavoured aqueous base with 10% 
alcohol.It is available in 120 ml bottles.The cost is 35INR. 
Tantum oral rinse  is used to relieve pain and inflammation 
associated with sore throats, mucositis, stomatitis periodontal 
surgery and with mouth sores caused by radiation therapy. 
Prompt relief from symptoms are seen immediately after rinse 
or gargle. 
3.0.9%w/v Normal saline:  
The saline used in the study was 0.9% w/v normal saline. 
Normal saline solution is prepared by adding approximately 1 
tsp of table salt  to 32 oz of water. It  contains no antimicrobial 
agents. The nominal pH is 5.5 (4.5 to 7.0). 0.9% Sodium 
Chloride Injection contains 9 g/L Sodium Chloride,) with an 
osmolarity of 308 mOsmol/L (calc). It  contains 154 mEq/L 
sodium and 154 mEq/L chloride. 
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INFORMED CONSENT FORM 
STUDY TITLE: 
  
EVALUATING THE EFFECTIVENESS OF PURE NATURAL 
HONEY AND 0.15 % BENZYDAMINE HYDROCHLORIDE ON 
RADIATION -INDUCED MUCOSITIS 
Name:       O.P.No: 
Address:       Serial No: 
Tel. no:       Age / Sex:  
I, ___________________________________________________ age ___ 
years Exercising my free power of choice, hereby give my consent to be 
included as a participant in the study “Evaluating the Effectiveness of Pure 
natural Honey and 0.15 % Benzydamine hydrochloride on Radiation – 
induced mucositis” 
I agree to the following: 
  
• I have been informed to my satisfaction about the purpose of the 
study and study procedures including investigations to monitor and 
safeguard my body function. 
• I agree to cooperate fully and to inform my doctor immediately if I 
suffer any unusual symptom. 
• I have informed the doctor about all medications I have taken in the 
recent past and those I am currently taking and other systemic illness 
that I have. 
Name of the patient              Name of the investigator 
Evaluating the Effectiveness of Pure natural Honey and 0.15% 
Benzydamine Hydrochloride on Radiation – induced Mucositis.                                          
 
HISTORY PROFORMA 
 
Serial no.:        Dental O.P. 
No:   
Name:                                                          Date: 
Address:                                                   Age / Sex: 
Occupation:        Tel. no: 
Income: 
Chief Complaints with Duration:       
Past Medical history: 
Past Surgical History:                                                                                                
Dental history: 
Personal History: 
GENERAL EXAMINATION: 
Nutritional Status:   Good/ Moderate / Poor  
HEAD AND NECK EXAMINATION:    
Extra – Oral Examination: 
CERVICAL LYMPH NODE EXAMINATION: 
 
Intra-Oral Examination: 
Oral hygiene: Poor /Fair /Good 
Teeth:                 Mobile:                          Pain:   Lost:  
Type of Lesion: 
 
Extension: 
 
Size: 
Associated /Preexisting / Precancerous conditions / Lesion: 
 
RADIOGRAPHIC FINDINGS: 
 
CLINICAL STAGING: T….N….M…. 
 
STAGE GROUPING:                                  
 
INVESTIGATIONS: 
 
Group 1 / 2 / 3 : 
WHO Mucositis Grading : 
Onset of Grade 1 (day) : 
Onset of Grade 2 (day) : 
Onset of Grade 3 (day) : 
Onset of Grade 4 (day) : 
Post RT end of First Week (Grade) : 
Post RT end of Second Week (Grade) : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1 : Armamentarium for Clinical Examination 
 
 
ORAL SQUAMOUS CELL CARCINOMA 
 
 
 
Squamous Cell Carcinoma of 
Lower Alveolus 
Squamous Cell Carcinoma of 
Buccal Mucosa 
  
Squamous Cell Carcinoma of Tongue Squamous Cell Carcinoma of Buccal Mucosa 
Fig  2: Oral Squamous cell Carcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3 : ORAL CANCER PATIENT ON RADIATION 
TREATMENT (CO60 equipment) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY MATERIALS 
 
                        
                       Pure Natural Honey       0.15%Benzydamine Hcl  
 
 
 
 
 
 
0.9% w/v Normal Saline 
Fig 4 
 
 
 
GROUP II 
 
  
Fig 14:Grade 1 (Erythema and Soreness) Fig 15 : Grade 2 (Erythema and Ulceration)
 
Fig 16 : Grade 3 (Erythema, Ulceration, 
Inability to take solid foods) 
Fig 17 : Grade 4 (Erythema, Ulceration, 
Alimentation not possible) 
 
 
Fig 18: Post RT end of 1st Week (Grade 2) Fig 19 : Post RT end of 2nd Week (Grade 1)
GROUP I 
 
  
Fig 8: Grade 1 (Erythema and Soreness) Fig 9 : Grade 2 (Erythema and Ulceration)
 
Fig 10: Grade 3 (Erythema, Ulceration, 
Inability to take solid foods) 
Fig 11 : Grade 4 (Erythema, Ulceration, 
Alimentation not possible) 
 
Fig 12 : Post RT end of 1st Week (Grade 1) Fig 13 : Post RT end of 2nd Week (Grade 1)
 
GROUP III 
    
Fig 20 : Grade 1 (Erythema and Soreness) Fig 21 : Grade 2 (Erythema and 
Ulceration)
Fig 22: Grade 3 (Erythema, Ulceration, 
Inability to take solid foods) 
Fig 23 : Grade 4 (Erythema, Ulceration, 
Alimentation not possible) 
 
Fig 24 : Post RT end of 1st Week (Grade 3) Fig 25 : Post RT end of 2nd Week (Grade 2)
TOPICAL APPLICATION OF STUDY MATERIALS  
 
  
Fig 5(a): Pure Natural Honey(20 ml) Fig 5(b): Topical application of pure 
natural honey  
 
Fig 6(a) : 0.15% w/v Benzydamine 
Hydrochloride(15 ml) 
Fig 6(b) : Topical application of 0.15% w/v 
Benzydamine Hydrochloride 
 
 
Fig 7(a) : 0.9% w/v Normal Saline(15 ml) Fig 7(b) : Topical application of 0.9% w/v 
Normal Saline
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 TABLE 2 (AGE IN YEARS)  
 
 N Mean p Value 
Group I 20 49.50 
0.198 
Group II 20 54.00 
Group III 20 55.55 
Total 60 53.02 
 
 
 
 
TABLE 3  
(GENDER DISTRIBUTION AMONG GROUPS) 
 
  Group 
Total 
(n=60) 
    
Group I
(n=20) 
Group II 
(m=20) 
Group III 
(n=20) 
SEX 
MALE 
Count 11 15 15 41 
% within 
Group 55.0% 75.0% 75.0% 68.3% 
FEMALE 
Count 9 5 5 19 
% within 
Group 45.0% 25.0% 25.0% 31.7% 
TOTAL 
Count 20 20 20 60 
% within 
Group 
100.0% 100.0% 100.0% 100.0% 
 
 
 
 
 
41 
 
 
TABLE 4 
 
SITE OF ORAL CANCER  
 
 Buccal mucosa Tongue 
Upper 
alveolus 
Lower 
alveolus
Floor 
of 
mouth
Maxillary 
antrum  
soft 
palate 
TOTAL
(n=20) 
Group 1 6 4 3 2 1 1 2 20 
Group 2 5 3 4 4 0 1 2 20 
Group 3 7 3 3 2 2 0 3 20 
 
 
 
TABLE 5 
 
TNM STAGING OF ORAL CANCER  
 
 Stage I 
Stage 
II 
Stage 
III 
Stage 
IV a 
Stage 
IV b 
Stage 
IV c Total  
Group 1 
(Honey) 0 1 1 16 2 0 20 
Group 2 
(Tantum) 0 1 0 17 2 0 20 
Group 3 
(Saline)  0 2 0 17 1 0 20 
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TABLE 6 
 
(ONSET OF GRADES I,II,III,& IV) 
 
 
TABLE 8 
 
(DURATION OF RADIOTHERAPY)
GRADE GROUP N MEAN (in days) 
GRADE 1 
Group I 20 13.95 
Group II 20 11.85 
Group III 20 11.50 
Total 60 12.43 
GRADE 2 
Group I 20 18.90 
Group II 20 16.15 
Group III 20 16.10 
Total 60 17.05 
GRADE 3 
Group I 20 25.25 
Group II 20 21.10 
Group III 20 21.35 
Total 60 22.57 
GRADE 4 
Group I 10 33.80 
Group II 19 26.74 
Group III 20 26.35 
Total 49 27.53 
 N MEAN (in weeks) P VALUE 
Group I 20 6.275  
Group II 20 6.175  
Group III  20 6.325 0.200 
Total 60 6.258  
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TABLE 7  
(MINIMUM,MAXIMUM AND MEAN DAYS OF ONSET OF GRADES I,II,III,& IV IN GROUPS) 
 SEX 
 Male Female 
 Minimum (in days) 
Maximum
(in days) 
Mean 
(in days) 
Minimum 
(in days) 
Maximum 
(in days) 
Mean 
(in days) 
Group Group I On set 12 16 13.91 12 19 14.00 
  Grade 2 14 21 18.18 17 27 19.78 
  Grade 3 16 34 24.45 22 36 26.22 
  Grade 4 30 38 35.50 25 36 30.50 
 Group II On set 10 15 11.73 12 13 12.20 
  Grade 2 14 21 16.20 15 18 16.00 
  Grade 3 18 27 21.40 19 22 20.20 
  Grade 4 23 36 27.43 23 26 24.80 
 Group III On set 10 14 11.67 10 13 11.00 
  Grade 2 14 18 15.93 15 19 16.60 
  Grade 3 17 24 21.20 20 24 21.80 
  Grade 4 24 29 26.33 24 30 26.40 
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TABLE 9 
(COMPARISON OF ONSET OF GRADES I, II, III IV BETWEEN 
GROUPS)  
Grades (I) Group (J) Group Mean Difference  (I-J) in Days P value 
Grade 1 Group I Group II 2.10(*) .000 
  Group III 2.45(*) .000 
 Group II Group I -2.10(*) .000 
  Group III .35 .679 
 Group III Group I -2.45(*) .000 
  Group II -.35 .679 
Grade 2 Group I Group II 2.75(*) .000 
  Group III 2.80(*) .000 
 Group II Group I -2.75(*) .000 
  Group III .05 .997 
 Group III Group I -2.80(*) .000 
  Group II -.05 .997 
Grade 3 Group I Group II 4.15(*) .000 
  Group III 3.90(*) .001 
 Group II Group I -4.15(*) .000 
  Group III -.25 .965 
 Group III Group I -3.90(*) .001 
  Group II .25 .965 
Grade 4 Group I Group II 4.66(*) .001 
  Group III 5.05(*) .000 
 Group II Group I -4.66(*) .001 
  Group III .39 .919 
 Group III Group I -5.05(*) .000 
  Group II -.39 .919 
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TABLE10 
(POST RT END OF FIRST WEEK) 
 
 Grade  
Group 
Total Group 
I 
Group 
II 
Group 
III 
Post 
RT 
end 
of 1st 
week 
1 
Count 4 0 0 4 
% within Post RT 1st week 100.0% .0% .0% 100.0% 
2 
Count 14 10 4 28 
% within Post RT 1st week 50.0% 35.7% 14.3% 100.0% 
3 
Count 2 10 11 23 
% within Post RT 1st week 8.7% 43.5% 47.8% 100.0% 
4 
Count 0 0 5 5 
% within Post RT 1st week .0% .0% 100.0% 100.0% 
Total 
Count 20 20 20 60 
% within Post RT 1st week 33.3% 33.3% 33.3% 100.0% 
 
TABLE 11  
(POST RT END OF SECOND WEEK) 
 Grade  
Group 
Total Group 
I 
Group 
II 
Group 
III 
Post 
RT 
end 
of 2nd  
week 
0 
Count 3 0 0 3 
% within Post RT 1st week 100.0% .0% .0% 100.0% 
1 
Count 15 12 5 32 
% within Post RT 1st week 46.9% 37.5% 15.6% 100.0% 
2 
Count 2 7 9 18 
% within Post RT 1st week 11.1% 38.9% 50.0% 100.0% 
3 
Count 0 1 6 7 
% within Post RT 1st week .0% 14.3% 85.7% 100.0% 
Total 
Count 20 20 20 20 
% within Post RT 1st week 33.3% 33.3% 33.3% 33.3% 
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TABLE 1 (Group 1) 
 
S. 
No. Name Age Sex Site 
TNM 
Staging Dose 
Duration 
of RT  
(in days) 
grade
1 
(Day)
grade 
2 
(Day) 
grade 
3 
(Day)
grade 
4 
(Day) 
post 
RT 1st 
(grade) 
post 
RT 2nd 
(grade) 
1 Balan 55 M Buccal Mucosa IV a 60 6 12 15 20 2 1
2 Kannan 54 M Tongue IV a 66 6.5 14 20 24 38 2 1
3 Thangavel 65 M Upper Alveolus IV a 66 6.5 13 17 27 37 2 1
4 Ramajayam   40 M Lower alveolus IV a 66 6.5 13 17 27 37 2 1
5 Saroja 50 F Buccal Mucosa IV a 60 6 14 20 28 36 2 1
6 Ranganathan      40 M Tongue IV a 60 6 12 14 16 30 1 1
7 Govindammal  30 F Floor of mouth IV a 66 6.5 14 27 31 2 1
8 Jayammal 47 F Maxillary Antrum IV b 66 6.5 19 23 36  2 1 
9 Krisnaveni 50 F Soft Palate IV a 60 6 14 18 24  2 1 
10 Kamala 51 F Buccal Mucosa IV a 60 6 14 19 24 1 0
11 Saluddin 60 M Buccal Mucosa IV a 60 6 15 19 24 1 0
12 Pakkiri 55 M Tongue IV a 60 6 16 21 34 2 1
13 Padma 45 F Upper Alveolus IV a 60 6 12 17 22 25 3 2 
14 Rajabader 48 M Lower alveolus III 66 6.5 15 20 24 2 1
15 Venkatesan        35 M Upper Alveolus IV a 66 6.5 15 20 25 2 0
16 Jaya 60 F Tongue IV a 60 6 12 17 23 2 1
17 Arumugam         40 M Buccal Mucosa II 70 7 14 18 24 2 1
18 Vasanta             55 F Soft Palate IV a 60 6 13 17 22 1 1
19 Ravindran 45 M Buccal Mucosa IV b 66 6.5 14 19 24 2 1
20 Amsavalli           65 F Soft Palate IV a 66 6.5 14 20 26 3 2
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TABLE 1 (Group 2) 
 
S. 
No. Name Age Sex Site 
TNM 
Staging Dose 
Duration 
of RT  
(in days) 
grade
1 
(Day)
grade 
2 
(Day) 
grade 
3 
(Day)
grade 
4 
(Day) 
post 
RT 1st 
(grade) 
post 
RT 2nd 
(grade) 
21 Ahamed 60 M Buccal Mucosa IV a 66 6.5 12 16 23 28 2 1
22 Natrajan 60 M Tongue IV a 60 6 15 21 24 36 2 1
23 Chellappan         52 M Upper Alveolus IV a 66 6.5 12 16 20 24 3 2
24 Lakshmi 55 F Buccal Mucosa IV a 60 6 12 16 19 24 3 1
25 Pazhanivel 45 M Tongue IV a 66 6.5 13 17 27 32 2 1
26 Mary 60 F Lower alveolus IV a 60 6 12 15 19 23 2 1
27 Ramaswamy 60 M Maxillary Antrum IV a 60 6 11 16 21 27 3 1 
28 Manibarathi 61 M Soft Palate IV a 60 6 10 15 18  3 2 
29 Sekar 40 M Buccal Mucosa II 60 6 11 14 20 25 2 1
30 Shahul 34 M Buccal Mucosa IV a 60 6 11 14 21 25 2 1 
31 Masanamuthu    66 M Tongue IV a 66 6.5 10 17 23 30 3 2
32 Kesavulu 55 M Upper Alveolus IV a 60 6 11 14 18 25 2 2
33 Durairaj 62 M Lower alveolus IV a 66 6.5 12 17 23 30 3 1
34 Gopal 60 M Upper Alveolus IV a 60 6 12 17 22 26 2 1
35 Umabaskar 39 M Buccal Mucosa IV b 60 6 12 16 21 27 3 2
36 Thangappan 68 M Upper Alveolus IV a 60 6 13 18 20 26 3 3 
37 Suguna 40 F Lower alveolus IV b 60 6 13 18 22 26 2 1 
38 Rasayyan 63 M Lower alveolus IV a 66 6.5 11 15 20 23 3 2
39 Lakshmiammal 45 F Soft Palate IV a 60 6 12 15 20 25 3 2
40 Saraswathi 55 F Upper Alveolus IV a 66 6.5 12 16 21 26 2 1
MASTER CHART 
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TABLE 1 (Group 3) 
 
S. 
No. Name Age Sex Site 
TNM 
Staging Dose 
Duration 
of RT  
(in days) 
grade
1 
(Day)
grade 
2 
(Day) 
grade 
3 
(Day)
grade 
4 
(Day) 
post 
RT 1st 
(grade) 
post 
RT 2nd 
(grade) 
41 Pazhanivelu 70 M Buccal Mucosa IV a 66 6.5 11 16 21 26 3 2
42 Subramani 45 M Buccal Mucosa IV a 60 6 12 16 20 24 3 2
43 Manickam 65 M Tongue IV a 60 6 12 17 24 29 3 2
44 Rajeswari 49 F Upper Alveolus IV a 60 6 11 15 20 24 2 1
45 Gowri 45 F Upper Alveolus IV a 60 6 10 15 20 24 2 1
46 Sigamani 60 M Lower alveolus IV a 66 6.5 11 14 19 24 3 2
47 Sadagopan 53 M Floor of mouth IV a 66 6.5 12 16 21 26 3 3
48 Munusamy 50 M Soft Palate IV b 66 6.5 12 15 20 24 3 2 
49 Babu 42 M Buccal Mucosa IV a 66 6.5 14 18 24 28 4 3 
50 Muniyan 57 M Tongue IV a 66 6.5 11 15 20 25 2 1
51 Perumal 67 M Upper Alveolus IV a 60 6 12 18 23 29 3 1 
52 Damodaran 57 M Lower alveolus IV a 60 6 13 14 17 26 3 2 
53 Rajendran 45 M Tongue IV a 66 6.5 10 14 20 27 4 3 
54 Mangammal 65 F Buccal Mucosa II 66 6.5 13 17 21 24 3 2
55 Lakshmi 50 F Buccal Mucosa IV a 66 6.5 10 19 24 30 2 1 
56 Sekar 42 M Soft Palate IV a 60 6 10 15 21 25 4 3
57 Chandran 55 M Floor of mouth II 66 6.5 11 16 21 26 3 2
58 Masanam 65 M Buccal Mucosa IV a 66 6.5 12 18 24 28 4 3
59 Kamakshi 46 F Soft Palate IV a 66 6.5 11 17 24 30 3 2
60 Gajendrababu 53 M Buccal Mucosa IV a 66 6.5 12 17 23 28 4 3
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RESULTS AND ANALYSIS 
The present study was directed to evaluate the day of 
onset of radiation-induced mucositis (Grade I of WHO 
mucositis Grading) and the severity, the progression to grades 
II, III, IV, in three groups during the course of radiotherapy for 
malignancy of oropharynx, of a total dose of radiation varying 
between 60 to 70 Gys, with a fractionation dose varying 
between 200 to 300 Gy per day in the range of 6 to 7 weeks. 
60 patients, who were to undergo radiotherapy for 
malignancy of oropharynx (Fig 7)  ,with field involving the oral 
and associated region selected for the study, there were 41 
males and 19 females .  The minimum age of male was 34 years 
and the maximum age was 70 years. The minimum age of 
female was 30 years and the maximum age was 65 years.  
(Table-1,3)  These patients were planned for radiotherapy. 
Cobalt- 60 equipment was used for radiation treatment. 
The equipment consists of a cylinder of diameter 2 cm, height 5 
cm. and is positioned in the Cobalt Unit with the circular end 
facing the patient. Cobalt-60 Gamma radiation typically has 
energy of about 1.2 MV, D-max being 0.5 cm. and a percentage 
depth of 55% at 10 cm. 
Cobalt units with low energy of gamma rays are used for 
treatment of head and neck cancers.  Conventional fractionated 
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radiation was delivered to the tumour volume at a dose rate of 2 
Gy per fraction, treating five fractions per week to a total 
period of 6-7 weeks. The weekly dosage was 10 Gy( Gray).The 
total dosage given varied from 60 to 70 Gy( 6000 to 7000 cGy 
Radiation source, modality, field size, treatment areas, total 
planned dose, number of fractions, days of irradiation were 
recorded in the structured proforma prepared for the study.  
The 60 patients were randomly divided into three groups 
(Table-1,3). All the patients received radiotherapy regimen as 
planned .The total dose of radiation varied between 60 to 70 Gy 
with a fractionation dose of 200 to 300 cGy per day in the range 
of 6 – 7 weeks.  
Group 1: 20 patients (n=20) 
Group 1 consisted of 11(51%) males and 9(45%) females. 
(Table-1,3). the mean age of both genders in group 1 is 49.50 
years(Table-2) .  The mean duration of RT in the Group 2 was 
6.275(+0.3024) (Table-8) In the group I, the patients were 
instructed to take 20 ml of pure natural honey 15 minutes 
before radiotherapy .They were instructed to slowly rinse the 
honey in their mouths, swish it around for 5 minutes duration 
,so as to make the honey in contact of the oral mucosa and 
slowly swallow so as to make contact with the pharyngeal 
mucosa. 
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The patients were exposed to therapeutic radiation. After 
15 mins of this, again 20 ml of pure natural honey is given to 
the patient to be followed as before. After 6 hours of the 
radiotherapy, the patients were instructed to again rinse with 20 
ml of pure natural honey. The patients take any food for one 
hour after the application of pure natural honey. 
Out of 20 subjects in Group 1, 4 patients developed grade 
I mucositis on the 12th day,3 patients developed gradeI 
mucositis on 13th day,8 patients  developed on 14th day,3 
patients developed mucositis on 15th day,1 patient developed 
grade I mucositis on 16th day,1 patient developed grade I 
mucositis on 19th day. 
In the maximum number of patients, the onset of 
mucositis was on the 14th day, totally 8 patients developed 
mucositis on 14th day. The mean onset of mucositis was on 14th 
day (Mean 13.95+1.638 days) (Table 6). 
Out of the 20 subjects,in group 1,1patient developed 
grade II mucositis on 14th day,1 patient developed grade II on 
15th day,5 patients developed grade II on 17th day,2 patients 
developed grade II on 18th day,3 patients developed gradeII on 
19th day,5 patients developed grade II mucositis on 20th day,1 
patient developed gradeII on 21st day,1 patient on 23rd day and 
1 patient on 27th day(Table 6). 
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The maximum number of patients developed grade II on 
17th and 20th days equally. The mean onset of grade II was on 
19th day (Mean 18.90+2.827 days). (Table 6). 
Out of the 20 subjects in group 1,1 patient developed 
grade III mucositis on 16th day,1 patient developed grade III on 
20th day,2 patients developed grade III on 22nd day,1 patient 
developed gradeIII on 23rd day,7  patients developed grade III 
on 24th day,1 patient developed grade III on 25th day, 1 patient 
developed gradeIII on 26th day,2 patients developed grade III 
on 27th day,1 patient developed grade III on 28th day,1 patient 
developed grade III on 31st day,1 patient developed grade III on 
34th day and 1 patient developd grade III on 26th day. The 
maximum number of patients (7 patients) developed grade III 
on 24th day. The mean onset of grade III mucositis was on 25th 
day (Mean 25.25+4.529 days). (Table 6). 
Only 6 patients developed grade IV of WHO mucositis 
grading in Group1.1 patient developed grade IV mucositis on 
25th day,1 patient developed grade IV mucositis on 30th day,1 
patient developed grade IV mucositis on 36th day,2 patients 
developed grade IV mucositis on 37th  day,1 patient developed 
grade IV mucositis on 38th day. The maximum number of 
patients developed grade IV on 37th day .The mean onset is on 
34th  day(Mean 33.80+4.195 days) (Table 6) 
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After the end of the course of the radiotherapy, the 
patients were instructed to follow the same procedure, of 
topical application of pure natural honey, for two weeks 
duration, after the last dose of RT. The 20 patients in group1 
were clinically examined for the gradings of mucositis at the 
end of 1st week of radiotherapy.  
Out of the 20 patients in the Group1,4 patients were 
having gradeI mucositis,14 patients were having grade II 
mucositis,2 patients were having grade III mucositis. Grade IV 
mucositis was seen in no patients. The maximum number of 
patients were in Grade II mucositis (14 patients out of total 20 
in grade I) (Table10). 
In the post RT end of 2nd week, all the 20 patients were 
clinically examined for the grade of mucositis. Out of the 20 
patients in Group1,3 patients were in grade 0 mucositis at the 
end of post RT 2nd week.15 patients were having grade 1 
mucositis,2 patients were having grade 2 mucositis. Grades 3 
&4 were not seen in any patient. (Table11) .   
Group 2(n=20):   
Group 2 had 15(75%) males and 5(25%) 
females(Table1,3) .  The mean age of both genders in group II 
was 54.00(Table-2).  The RT regimen consisted of a total dose 
of radiation varying between 60 t0 70 Gy with a fractionation 
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dose of 200 to 300 cGy per day in the range of 6-7 weeks. The 
mean duration of RT in the Group 2 was 6.175(0.2447) in 
weeks. (Table-9) 
         Patients were instructed to rinse with 15 ml of 0.15% 
benzydamine Hcl without dilution,for 5 minutes duration,15 
minutes before and 15 mins after RT. The patient should be 
instructed to keep the rinse in contact with the oral mucosa for 
atleast 5 minutes duration, and then spit it out.  
The patients were exposed to therapeutic radiation. After 
15 mins of this, the patients were asked  again  to rinse with 15 
ml of 0.15%w/v benzydamine hydrochloride , for 5 minutes 
duration and then spit it out. After 6 hours of the radiotherapy, 
the patients were instructed to again rinse with 0.15% w/v 
benzydamine hydrochloride for a duration of 5 minutes and then 
spit it out. The patients were instructed not to take any food for 
one hour after the application of  benzydamine hydrochloride. 
Out of the 20subjects in the group 2, 2 patients developed 
grade I mucositis on the 10th day,5 patients developed grade I 
mucositis on the 11th day,9 patients developed grade I mucositis 
on 12th day,3 patients developed grade I mucositis on 13th day, 
1 patient developed grade I mucositis on 15th day. The mean 
onset was on 12th day (Mean 11.85+1.137 days). (Table-6).  
Out of the 20 subjects, 3 patients developed grade II on  
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14th day,4 patients developed grade II on 15th day,6 
patients developed grade II on 16th day,4 patients on 17th day,2 
patients on 18th day,1 patient on 21st day. The mean onset of 
grade II was on 16th day (Mean 16.15+1.663 days) (Table-6). 
Out of the 20 subjects, 2 patients developed gradeIII on 
18th day,2 patients developed grade III on 19th day,5 patients 
developed grade III on 20th day,4 patients developed grade III 
on the 21st day,2 patients developed grade III on 22nd day,3 
patients developed grade III on the 23rd day,1 patient developed 
grade III on the 24th day,1 patient developed grade III on the 
27th day(Table-6) . 
The mean onset of grade III in group 2 was on the21st day 
(Mean 21.10+2.174 days). Out of the 20 subjects in group 2, 19 
patients developed Grade IV mucositis. One person did not 
develop grade IV mucositis. Out of the 19 patients,2 patients 
developed grade IV on the 23rd day,2 patients developed grade 
IV on 24th day,4 patients developed grade IV mucositis on the 
25th day,4 patients developed grade IV mucositis on the 26th 
day,2 patients developed grade IV mucositis on 27th day,1 
patient developed grade IV mucositis on 28th day,2 patients 
developed grade IV mucositis on the 30th day,1 patient 
developed grade IV mucositis on the 32nd day,1 patient 
developed grade IV mucositis on the 36th day (Table-6). The 
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mean onset of Grade IV in group 2 was on 27th day (Mean 
26.74+3.280 days) 
In the post RT end of 1s t week, all the 20 patients in 
group 2 were clinically examined for the grade of mucositis. 
Out of the 20 patients in the group2, grades 0 or 1 were not 
seen in any of the patients.10 patients were having grade II 
mucositis.10 patients were with grade III mucositis, no patient 
was with grade IV mucositis (Table-10).  
In the post RT end of 2nd week, all the 20 patients in 
group 2 were clinically examined for the grade of mucositis. 
Out of the 20 patients in group 2, No patient was with grade 0 
mucositis.12 patients  were having grade I mucositis.7 patients 
were with grade II mucositis,1 patient was with grade III 
mucositis, no patients were seen to have grade IV 
mucositis.(Table-11) 
GROUP 3(n=20): 
Group3 had 20 patients. There were 15(75%) males and 
5(25%) females (Table 1) . The mean age of both genders in 
group 3 was 55.55 years (Table-3).  The RT regimen consisted 
of a total dose of radiation varying between 60 t0 70 Gy with a 
fractionation dose of 200 to 300 cGy per day in the range of 6-7 
weeks. The mean duration of RT in the Group 3 
was6.325(0.2447) (Table-9). 
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 Patients were instructed to rinse with 20ml of  0.9%w/v 
Normal saline for 5 minutes duration. The patient should be 
instructed to keep the rinse in contact with the oral mucosa for 
atleast 5 minutes duration, and then spit it out.  
    The patients were exposed to therapeutic radiation .After 
15 mins of this, the patients were asked  again  to rinse with 20 
ml of 0.9%w/v Normal saline, for 5 minutes duration and then 
spit it  out. After 6 hours of the radiotherapy, the patients were 
instructed to again rinse with 20 ml0.9%w/v of normal saline 
for a duration of 5 minutes and then spit it out. 
Out of the 20 patients in Group 3, 4 patients developed 
grade I mucositis on the 10th day,6 patients developed grade I 
mucositis on the 11th day,7 patients developed grade I mucositis 
on the 12th day,2 patients developed grade I mucositis on the 
13th day,1 patient developed grade I mucositis on the 14th day. 
The mean onset of grade I mucositis in group 3 was on 12th day 
(Mean 11.50+1.100 days) (Table-6)  
Out of the 20 subjects in group 3,3 patients developed 
grade II on the 14th day,5 patients developed grade II on 15th 
day,4 patients developed grade III on 16th day,4 patients 
developed grade II on 17th day,3 patients developed grade II on 
18th day,1 patient developed grade II on 19th day. The grade II 
was on 16th day (Mean 16.10+1.483 days) (Table-6) 
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Out of the 20 subjects in Group 3,1 patient developed 
grade III on 17th day,1 patient developed grade III on 19th day,6 
patients developed grade III on 20th day,5 patients developed 
grade III on 21st day,2 patients developed grade III on 23rd 
day,5 patients developed grade III on 24th day. The mean onset 
of grade III in group3 was on 21st day (Mean 21.35+2.007) 
(Table-6) 
Out of the 20 subjects in groupIII,all  the subjects 
developed grade IV mucositis.This shows that the control group 
had a minimal protection against incidence of grade IV 
mucositis (Table-6). 
Out of the 20 subjects,6 patients developed grade IV 
mucositis on the 24th day,2 patients developed grade IV 
mucositis on the 25th day,4 patients  developed  grade IV 
mucositis on the 26th day,1 patient developed grade IV 
mucositis on the 27th day,3 patients  developed grade IV 
mucositis on 28th day,2 patients developed grade IV mucositis 
on the 29th day,2 patients developed grade IV mucositis on the 
30th day. The mean onset of Grade IV mucositis was on 26th day 
(Mean 26.35+2.134 days) (Table-6) 
In the post RT end of 1s t week, all the 20 patients in 
group 3 were clinically examined for the grade of mucositis. 
Out of the 20 patients in the group3,no patients were with grade 
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0 and grade I mucositis. 4 patients were having gradeII 
mucositis.11 patients were with grade III mucositis,5 patients 
were with grade IV mucositis (Table-10).  
In the post RT end of 2nd week, all the 20 patients in 
group 3 were clinically examined for the grade of mucositis. 
Out of the 20 patients in group 3, 5 patients were having gradeI 
mucositis.9 patients were with grade II mucositis,6 patients 
were with grade III mucositis. None were with grade IV 
mucositis (Table-11). 
Comparison of duration of radiotherapy between groups: 
The duration of RT in the 60 patients were between 6-7 
weeks. The mean duration of RT, in weeks, in groups 1,2,3 
were 6.275(+0.3024). 6.175(0.2447), 6.325(0.2447) 
respectively. The p value is 0.200(Not significant at 5%) that 
shows that there is no major difference in the duration of RT 
between the three groups. (Table-9) 
Comparison of onset (grade 1 of WHO mucositis grading 
system) between groups : 
The mean onset of mucositis(Grade I ),clinically seen as 
Erythema without ulceration with symptoms of soreness in the 
oral mucosa, in the three groups were noted. The mean onset of 
mucositis in Group 1 was on 14th day (Mean 13.95+1.638 days) 
The mean onset of mucositis in Group 2 was on 12th day (Mean 
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11.85+1.137 days) The mean onset of mucositis in Group 3 was 
on 14th day (Mean 11.50+1.100 days) The mean difference on 
onset between Groups 1 & 3 was 2.45 days The p-value between 
Group1 & 3 was <0.001. The mean difference on onset between 
Groups 2 & 3 was 0.35 days The p-value between Group2 & 3 
was 0.679. The mean difference on onset between Groups 1 & 2 
was 2.10 days. The p-value between Group1 & 2 was <0.001 . 
(Table-8)  
The statistical anlaysis of the days of onset between 
groups shows that group1 (Pure natural Honey group) has a 
delayed onset of mucositis in comparison to 
group2(0.15%benzydamine hydrochloride group) and group 
3(0.9% normal saline). 
There is no major difference in the onset between groups 
2 & 3.Hence, pure natural honey delays the onset of radiation-
induced mucositis. 
Comparison of onset of grade II (WHO mucositis grading 
system) between groups: 
The mean onset of grade II mucositis,clinically seen as 
Erythema with ulceration with symptoms of soreness in the oral 
mucosa, in the three groups were noted. The mean onset of 
grade II mucositis in Group 1 was on 19th day (Mean 
18.90+2.827 days) The mean onset of grade II mucositis in 
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Group 2 was on 16th day (Mean 16.15+1.663 days) The mean 
onset of grade II mucositis in Group 3 was on 16th day(Mean 
16.10+1.483 days) (Table-6)  The mean difference on onset of 
grade II between Groups 1 & 3 was 2.80 days. 
The p-value between Group1 & 3 was <0.001. The mean 
difference on onset of grade II between Groups 2 & 3 was 0.05 
days The p-value between Group2 & 3 was  0.997 The mean 
difference on onset of grade II  between Groups 1 & 2 was 2.75 
days The p-value between Group1 & 2 was <0.001(Table-8) 
The statistical anlaysis of the days of onset of grade II 
between groups shows that group1 (Pure natural Honey group) 
has a delayed onset of grade II mucositis in comparison to 
group2(0.15%benzydamine hydrochloride group) and group 
3(0.9% normal saline). 
There is no major difference in the onset of grade II 
between groups 2 & 3.Hence, pure natural honey delays the 
onset grade II of radiation-induced mucositis. 
Comparison of onset of grade III (WHO mucositis grading 
system) between groups : 
The mean onset of grade III mucositis, clinically seen as 
Erythema with ulceration with symptoms of soreness in the oral 
mucosa, and functional impairment to take solid foods, in the 
three groups were noted. The mean onset of grade III mucositis 
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in Group 1 was on 25th day(Mean 25.25+4.529 days) The mean 
onset of grade III mucositis in Group 2 was on 21st  day(Mean 
21.10+2.174 days) The mean onset of grade III mucositis in 
Group 3 was on 21st  day(Mean 21.35+2.007 days) (Table-6)  
The mean difference on onset of grade III between Groups 
1 & 3 was 3.90 days. The p-value between Group1 & 3 was 
<0.001 The mean difference on onset of grade III between 
Groups 2 & 3 was -0.25 days The p-value between Group2 & 3 
was  0.965(Table-7) The mean difference on onset of grade III  
between Groups 1 & 2 was 4.15 days The p-value between 
Group1 & 2 was <0.001(Table-8)  
The statistical anlaysis of the days of onset of grade III 
between groups shows that group1(Pure natural Honey group) 
has a delayed onset of grade III mucositis in comparison to 
group2(0.15%benzydamine hydrochloride group) and group 
3(0.9% normal saline).  
Comparison of onset of grade IV (WHO mucositis grading 
system) between groups : 
The mean onset of grade IV mucositis, clinically seen as 
Erythema with ulceration with symptoms of soreness in the oral 
mucosa,and functional impairment to take solid foods and 
liquids also(alimentation not possible), in the three groups were 
noted. The mean onset of grade IV mucositis in Group 1 was on 
60 
 
34th  day(Mean 33.80+4.195 days) The mean onset of grade IV 
mucositis in Group 2 was on 27th   day(Mean 26.74+3.280 days) 
The mean onset of grade IV mucositis in Group 3 was on 26th   
day(Mean 26.35+2.134 days) (Table-6)  
The mean difference on onset of grade IV between Groups 
1 & 3 was 7.06 days. The p-value between Group1 & 3 was 
<0.001 The mean difference on onset of grade IV between 
Groups 2 & 3 was 0.39 days The p-value between Group2 & 3 
was  0.919 The mean difference on onset of grade IV  between 
Groups 1 & 2 was 7.45 days The p-value between Group1 & 2 
was <0.001(Table-8)  
The statistical analysis of the days of onset of grade IV 
between groups shows that group1 (Pure natural Honey group) 
has a delayed onset of grade IV mucositis in comparison to 
group2(0.15%benzydamine hydrochloride group) and group 
3(0.9% normal saline). Another finding in the present study is 
that out of 20 patients in group1(pure natural honey group),only 
6 patients developed intolerable grade IV mucositis. 
Comparison of Post-RT end of 1st  week in groups :  
In the post RT end of 1st week,grade I was seen in 4 
patients( All patients in Group1) at the end of 1s t week post 
radiotherapy. None of the patients in the Groups 2&3 were 
clinically seen with grade 1. Grade II  clinically seen  in 28 
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patients (group 1-14 patients,Group 2-10 patients,group3-4 
patients) at the end of 1st  week post radiotherapy Grade III 
clinically seen as erythema and soreness with ulceration and 
symptoms of inability to take solid  foods, were seen in 23 
patients (Group 1- 2 patients group2- 10 patients,group3- 11 
patients) at the end of 1s t  week post radiotherapy Grade IV 
clinically seen as erythema, soreness and ulceration and 
functional impairment to take solids and liquid diet also 
(alimentation not possible),was seen in5 patients(Group 3- 5 
patients) at the end of 1s t  week post radiotherapy.  
At the end of 1s t week post radiotherapy, Out of 20 
patients in the Group 1, only 2 patients were with grade III 
mucositis, compared to 10 patients in the group2 and 11 
patients in group 3.This shows the low incidence of grade III in 
the group 1 compared to groups 2 & 3. Grade IV was seen in 5 
patients (Group 3 – 5 patients) (Table-10) 
Comparison of Post-RT end of 2nd week in groups 1,2&3: 
In the post RT end of 2nd week, grade 0 clincally seen as a 
normal mucosa was seen in 3 patients all from group I. In the 
post RT end of 2nd week, grade I, was seen in 32 
patients(Group1- 15 patients, group 2-12 patients, group 3-5 
patients). at the end of 2nd week post radiotherapy Grade II  
clinically was seen in 18 patients (group 1- 2patients,Group 2- 
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7 patients,group3- 9 patients) at the end of 2nd  week post 
radiotherapy. Grade III clinically was seen  in 7 patients                  
(Group 1- no patients group2- 1 patient,group3- 6 patients.) at 
the end of 2nd  week post radiotherapy None of the patients 
were of grade IV ,out of the 60 patients at the end of the 2nd 
week post-radiotherapy. 
At the end of 2nd   week post radiotherapy, Out of 20 
patients in the Group 1 ,no  patients were with grade III 
mucositis, compared to 1 patient in the group2 and 6 patients in 
group 3(Table-11)  
The results from the present study reveal that pure natural 
honey delays the onset of grade 1 of radiation-induced 
mucositis. The severity of radiation-induced mucositis, 
assessed by the number of patients with symptomatic grade IV, 
is also reduced by the use of pure natural honey. Thus, topical 
application of natural honey is a simple and cost-effective 
treatment in radiation mucositis. 
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Chart 3 : Site Of Oral Cancer 
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Chart 4 : TNM Staging Of Oral Cancer  
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Chart 8 : ONSET OF GRADES IV 
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DISCUSSION 
A large number of malignancies of oral and oro-
pharyngeal region are radio-sensitive squamous cell carcinomas 
and hence irradiation is used as a primary treatment modality, 
for the management of these malignancies. There is always 
some degree of damage to normal tissues as a consequence of 
the therapeutic regimen (which may go as high as 60-70 Gy) 
Oral complications arise from radiation injury to the Oral 
mucosa and tongue, salivary glands, oral musculature and 
alveolar bone. Radiation-induced mucositis is a normal 
accompaniment of radical radiotherapy to the head and neck 
region. Normally, the oral mucosa has a relatively high cell 
turnover rate. Exposure to ionizing radiation leads to mucosal 
erythema, small whitish patches6 and ultimately results in 
confluent mucositis. In the later phases, oral ulceration and 
bleeding become a dose-limiting toxicity. Mucositis is a result  
of imbalance between cell loss and cell proliferation. The 
intensity of mucositis can be altered by new fractionation 
schedules, concurrent chemo-radiotherapy and co-morbid 
medical conditions. Bacterial colonization in the oralmucosa 
can aggravate the preexisting mucositis. Endotoxins released 
from the gram-negative bacilli are potent mediators of the 
inflammatory process in the oral mucosa. oropharyngeal flora 
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too contributes to the radiation-induced mucositis9 ,41 other  
factor like poor oral hygiene and tobacco chewing and smoking 
habits can contribute to radiation- induced mucusitis . Various 
agents have been tried for management of radiation-induced 
mucositis. The agents recommended or tested for the prevention 
and management of radiation induced mucositis, have targeted 
specific pathways and they include mucosal coating agents, 
anti-inflammatory agents, antimicrobials, immunomodulators, 
anesthetics and analgesics, and other agents that are difficult to 
classify. These locally applied as well as systemically taken 
agents have been supportive at most, consisting of measures to 
alleviate pain and improve discomfort, support adequate 
hydration and, in some, the ability to eliminate secondary 
infections89. 
In 1981,WHO published grading criteria for 28 acute 
toxicities, including mucositis41.Subsequently,the National 
Cancer Institute’s(NCI) common toxicity criteria was published 
in 1983,which included 49 chemotherapy related toxicity 
criteria scales along with mucositis.  85  
In the present study, 60 patients were selected for the 
study. There were 41 (68.3%) males and 19 (31.7%) females. 
The minimum age of male was 34 years and the maximum age 
was 70 years. The minimum age of female was 30 years and the 
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maximum age was 65 years. These patients were planned for 
radiotherapy. Cobalt- 60 equipment was used for radiation 
treatment. 
Conventional fractionated radiation was delivered to the 
tumour volume at a dose rate of 2 Gy per fraction, treating five 
fractions per week to a total period of 6-7 weeks. The weekly 
dosage was 10 Gy( Gray).The total dosage given varied from 60 
to 70 Gy( 6000 to 7000 cGy) 
Radiation source, modality, field size, treatment areas, 
total planned dose, number of fractions, days of irradiation 
were recorded in the structured proforma prepared for the 
study. The 60 patients were randomly divided into two groups. 
Group 1(n=20): twenty patients in Group 1 were instructed to 
rinse with 20 ml of pure natural honey,15 minutes before,15 
minutes after and 6 hours post-RT, during the course of 
radiotherapy. 
Group 2(n=20): twenty patients in Group 2 were 
instructed to rinse with 15 ml of 0.15%w/v benzydamine 
hydrochloride ,15 minutes before,15 minutes after and 6 hours 
post-RT, during the course of radiotherapy. 
Group 3(n=20): twenty patients in Group 3 were 
instructed to rinse with 15 ml of 0.9% normal saline,15 minutes 
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before,15 minutes after and 6 hours post-RT, during the course 
of radiotherapy. 
During the course of radiotherapy, two patients in the 
group 3 were found to be having oral candidiasis, during the 
period of study. They were advised good oral hygiene with 
topical 1% Clotrimazole mouth paint. 
The onset of Grade I (WHO Mucositis Grading) was 
clinically observed in all the 3 groups, and severity is clinically 
observed by the days of onset of grades II,III,& IV in the 3 
groups and also the number of patients with more severe 
clinical and functional grades of III & IV. 
The present study revealed that patients in Group 1(Pure 
natural honey group) had a delayed onset of mucositis, 
compared to Group 2 (0.15% w/v benzydamine Hcl group) and 
Group3 (0.9% normal saline group) ( 14th day in group1 
compared to 12th day in group 2 and group. The p-value 
between group1 & 3 is 0.001, between group2&3 is 0.679, and 
between 1&2 was <0.001. 
The group1 had a statistically significant difference on 
the onset, compared to the groups 2 and 3. The present study 
revealed that patients in Group 1(Pure natural honey group) had 
a late onset of Grade II mucositis, compared to Group 2(0.15% 
benzydamine Hcl group) and Group3 (0.9% normal saline 
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group)( 19th day in group1 compared to 16th day in group 2 and 
16th day in group3. The p-value between group 1 & 3 is < 
0.001, between group 2 & 3 is 0.997, and between 1 &2 was 
<0.001. 
The group1 had a statistically significant difference on 
the onset of grade II, compared to the groups 2 and 3. The 
present study revealed that patients in Group 1(Pure natural 
honey group) had a late onset of Grade III mucositis, compared 
to Group 2(0.15% benzydamine Hcl group) and Group3(0.9% 
normal saline group)( 25th day in group1compared to 21st  day 
in group 2  and 21st  day in group3. The p-value between 
group1 & 3 is <0.001, between group2&3 is 0.965,and between 
1&2 was <0.001. 
The group1 had a statistically significant difference on 
the onset of grade III, compared to the groups 2 and 3. The 
present study revealed the out of 20 patients in group 1, only 6 
(30%) patients developed more debilitating  grade IV mucositis, 
compared to group 2 whereby 19 patients out of the 20 patients 
developed grade IV mucositis and group 3  Whereby all the 20 
patients developed grade IV mucositis. This observation is 
consistent with the study by B.M.Biswal, A.Zakaria, 
N.M.Ahmad in 20026 , wherein they reported that there is 
significant reduction in symptomatic grade III and IV mucositis 
68 
 
in honey treated group. In the same study, the mean onset of 
mucositis both in study and control groups was 3 weeks (No 
significant difference on the onset of mucositis). 4  In this study, 
the mean onset of mucositis in honey treated patients(Group 1) 
were on 14th day, compared to 12th day in 0.15% benzydamine 
treated (Group 2) patients and 12th day. The difference between 
Group 1 and the groups 2&3 was statistically significant 
(p=<0.001).  
The observation of 14 (70%) patients of the total 20 
patients in group 1 ,to have not developed grade IV mucositis, 
in our study, also is consistent with the study by Rashad U M et 
al in 2006 ,wherein no patients in the study arm (honey treated) 
developed grade IV mucositis63. 
This observation is also consistent with study by 
B.Khanal, M.Baliga,N.Uppal in 2009,wherein it was observed 
that the proportion of patients with intolerable oral mucositis 
was lower in honey group compared with controls(p=0.000)32. 
M.Motallebnejad et al in 2004 observed that, in the honey 
treated group, the mucositis score at the end of each week was 
significantly lower than the control group.43 
In this study, we analysed the grades of mucositis 
everyday, the day of onset of mucositis (grade 1 of WHO 
mucositis grading) and the days of onset of grade II, III and IV. 
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The present study also revealed that at the end of post 
radiotherapy 1st week there was low occurrence of GradeIII in 
the honey group compared to 0.15% benzydamine and 0.9% 
saline groups. 
Honey forms primarily from the transformation and 
concentration of  nectars from flowers by two processes: The 
interaction with the upper  digestive tract secretion of 
honeybees and  concentration by water loss(>80%) in beehives. 
They contain moisture, fructose, glucose, sucrose, maltose and 
other compounds, along With trace elements.60 
In the recent past, honey has been used for the treatment 
of burn wound, infected surgical wounds, childhood diarrhea, 
eye infections, etc56  
The ancient Egyptians and Greeks used honey for wound 
care, and a broad spectrum of wounds are treated all over the 
world with natural unprocessed honey from different sources.56 
The philosophy of using honey in radiation mucositis was 
derived from the basic research and clinical observation of 
rapid epithelization in tissue injuries .  8 ,  57  
Coating a wound with honey retards tissue oxygenation by 
sealing the damaged mucosa from air (oxygen).this could 
dampen pain within 30 seconds after application56. 
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Important factors that influence the effectiveness of 
honey are (1) Its hygroscopic nature,(2) Acidic pH prevents 
bacteria growth when applied to the mucosa;(3) Inhibin 
(hydrogen peroxide) converted from glucose oxydase and 
gluconic acid;(4)Enzymes (growth factors) and tissue-nutitive 
minerals and vitamins help repair tissue directly. The reduction 
of radiation-induced mucositis in honey-treated patients might 
be due to the bacteriostatic effect of viscid honey. Pure honey 
is acidic, with a ph of around 3.9.The solubility reducing factor 
present in honey can activate in absence of saliva. Honey 
applied on radition-induced xerotic mucosa increases the micro-
hardness of enamel, thereby preventing caries. Hence, it  has 
been postulated that honey is less cariogenic in dry mouth 
patients83.   
In a report of the Russian academy of Medical Science, 
patients treated with honey laminolact in uterine cancer patients 
undergoing radiotherapy showed significant decrease in the 
severity of radiation-induced intestinal morbidity84 .   
Pure honey is ubiquitous, cheap and natural, and exhibits 
antibacterial, analgesic and tissue nutritive factors to stimulate 
re-epithelialisation in the damaged mucosa, and is thereby a 
justified agent to try in radiation mucositis.  
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SUMMARY AND CONCLUSION 
In the present study, 60 patients were selected for the 
study. There were 41 (68.3%) males and 19 (31.7%) females. 
The minimum age of male was 34 years and the maximum age 
was 70 years. The minimum age of female was 30 years and the 
maximum age was 65 years. These patients were planned for 
radiotherapy. Cobalt- 60 equipment was used for radiation 
treatment. Radiation source, modality, field size, treatment 
areas, total planned dose, number of fractions, days of 
irradiation was recorded in the structured proforma prepared for 
the study.  The 60 patients were selected for the study all the 
patients were given habit counseling regarding stopping of the 
habit of the tobacco and were advised on basic oral hygiene. 
These 60 patients were randomly divided into three groups. 
Twenty patients in Group 1 were instructed to rinse with 
20 ml of pure natural honey,15 minutes before,15 minutes after 
and 6 hours post-RT, during the course of radiotherapy.  
Twenty patients in Group 2 were instructed to rinse with 15 ml 
of 0.15%w/v benzydamine hydrochloride ,15 minutes before,15 
minutes after and 6 hours post-RT, during the course of 
radiotherapy. Twenty patients in Group 3 were instructed to 
rinse with 15 ml of 0.9% normal saline, 15 minutes before,15 
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minutes after and 6 hours post-RT, during the course of 
radiotherapy. 
The onset of Grade I (WHO Mucositis Grading) was 
clinically observed in all the 3 groups, and severity is clinically 
observed by the days of onset of grades II,III,& IV in the 3 
groups and also the number of patients with more severe 
clinical and functional grades of III & IV . 
The onset of grades I,II,III&IV were compared within 
groups. The grades during end of post-RT 1st  week and 2nd 
week were compared between groups. 
Statistical analysis were done using SPSS version 15 days 
of onset of grades I, II, III & IV were compared between groups 
1, 2 & 3. From the presence study, we found usefulness of pure 
natural honey in the management of symptomatic radiation 
mucositis. As this agent is effective in radiation mucositis, the 
same treatment could be useful in the management of 
chemotherapy-induced oral stomatitis/mucositis and in 
mucositis of bone marrow transplant patients. The philosophy 
of management in the above conditions is similar. The further 
issue in the use of medicinal honey is quality assurance of 
natural honey-which might be different in different geographic 
locations-and the source of pollens. 
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As the future multi-modality approach to cancer lies in 
chemo-radiotherapy and altered fractionation schemes, 
prevention of oral mucositis is very important in its 
management. Honey could be a simple, potent and inexpensive 
agent, which is easily available, especially in the present Indian 
scenario for the management of this morbidity. However, 
further randomized studies are essential to validate our 
findings. 
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